GM Asked to Disclose Donations to Nonprofits in Wake of Awards-for-Barra Controversy

Barra Appeal of ConscienceToday I sent the following letter to Theodore Solso, Chairman of the GM Board:

As a shareholder, the National Legal and Policy Center (NLPC) asks General Motors (GM) to disclose all its contributions to charitable and nonprofit organizations by the company, the General Motors Foundation, or any other entity.

This request is prompted by the acceptance of various awards by CEO Mary Barra offered by charitable and nonprofit organizations at the same time some of the groups are recipients of large cash donations from GM.

The company has vigorously publicized these awards, apparently as part of a campaign to promote and rehabilitate Ms. Barra’s image in the wake of the ignition switch recall delay, for which the death toll continues to rise. Unfortunately, this campaign has backfired and resulted in negative publicity for the company.  

On November 10 of last year, we asked the National Women’s History Museum (NWHM) …

NLPC Shareholder Proposal Challenges Pfizer’s Support of ObamaCare

Ian Read photoNLPC has filed a shareholder proposal challenging Pfizer’s support for ObamaCare. The resolution actually asks for a report on Pfizer’s lobbying priorities. Here is the supporting statement submitted to Pfizer for inclusion in the proxy:

Pfizer played a key role in the passage of ObamaCare, even though a majority of Americans were opposed. CEO Jeffrey Kindler organized pharmaceutical CEOs in support of the bill, promoted a massive advertising campaign, and partnered with Left-wing groups normally hostile to Pfizer’s interests. For these actions, he received a multi-million dollar bonus.

According to media reports, Pfizer and other companies in 2009 made an $80 billion deal with the Obama administration. In return for support of ObamaCare, the companies received promises of a guarantee of customers and insulation from certain kinds of competition. This kind of back room dealing corrupts the political process, generates public outrage, and is inappropriate for an institution like Pfizer